Table 2 Factors associated with the persistence of imatinib initial therapy
Characteristics | Non-persistenta | Persistent | χ2 | OR for being persistent (95% CI) | p value |
|---|---|---|---|---|---|
(n = 479) | (n = 303) | (p-value) | |||
Age at diagnosis, y, n (%) | 2.08 (0.15) | ||||
≥40, | 308 (64.3) | 210 (69.3) | 1.4 (0.9 to 2.1) | 0.15 | |
<40 | 171 (35.7) | 93 (30.7) | 1 (referent) | ||
Gender, n (%) | 0.44 (0.51) | ||||
Male | 281 (58.7) | 185 (61.1) | 1.4 (0.9 to 2.1) | 0.10 | |
Female | 198 (41.3) | 118 (38.9) | 1 (referent) | ||
Charlson comorbidity score, n (%) | 1.39 (0.24) | ||||
>0 | 215 (44.9) | 123 (40.6) | 0.8 (0.5 to 1.1) | 0.16 | |
=0 | 264 (55.1) | 180 (59.4) | 1 (referent) | ||
CML diagnosis, n (%) | 11.97(<0.001) | ||||
≥2004 | 260 (54.3) | 126 (41.6) | 4.1 (2.2 to 7.9) | <.0001 | |
<2004 | 219 (45.7) | 177 (48.4) | 1 (referent) | ||
CML severity, n (%) | 7.60 (0.06) | ||||
Unknown | 28 (5.9) | 24 (7.9) | 0.6 (0.2 to 1.6) | 0.20 | |
Low | 2 (0.4) | 2 (0.7) | 1.4 (0.1 to 19.0) | 0.77 | |
Moderate | 378 (78.9) | 251 (82.8) | 1.5 (0.8 to 3.0) | 0.30 | |
High | 71 (14.8) | 26 (8.6) | 1 (referent) | ||
Prior treatment, n (%) | |||||
Hydroxyurea | 342 (71.4) | 225 (74.3) | 0.76 (0.38) | 1.8 (1.1 to 2.8) | 0.02 |
Busulfan | 8 (1.7) | 9 (3.0) | 1.48 (0.22) | 0.5 (0.1 to 2.0) | 0.34 |
IFNα/Ara-C | 72 (15.0) | 75 (24.8) | 11.49(<0.001) | 1.9 (1.1 to 3.3) | 0.02 |
Mean time to imatinib initiation, month (SD) | 14.1 (19.6) | 15.4 (19.4) | 0.89 (0.37)d | 1.0 (0.99 to 1.02) | 0.42 |
Mean starting daily dose, mg/day (SD)b | 362 (141) | 375 (108) | 1.35 (0.18) d | 1.1 (0.97 to 1.34) | 0.11 |
Mean treatment duration, months (SD) | 16.5 (16.8) | 41.2 (14.2) | 21.94 (<.0001) d | 1.1 (1.09 to 1.13) | <.0001 |
HSCT post-index date, n (%) | 35 (7.3) | 2 (0.7) | 18.19(<.0001) | 0.1 (0.02 to 0.5) | 0.01 |